| P50 | author | Julio Montaner | Q1712378 |
| | STOP HIVAIDS Study Group | Q125271728 |
| | Robert S Hogg | Q37837778 |
| | Bohdan Nosyk | Q90801622 |
| | Benita Yip | Q114738779 |
| P2093 | author name string | Viviane D Lima | |
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 |
| | Development and validation of a composite programmatic assessment tool for HIV therapy | Q28485260 |
| | A flexible two-part random effects model for correlated medical costs | Q30433683 |
| | The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study | Q33598342 |
| | Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel | Q33824632 |
| | Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study | Q34126545 |
| | Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. | Q34289633 |
| | HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions | Q34339471 |
| | The direct costs of HIV/AIDS care | Q34497622 |
| | The survival benefits of AIDS treatment in the United States | Q34533291 |
| | The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic | Q34554572 |
| | Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. | Q34719319 |
| | Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection | Q34740804 |
| | Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults | Q35610449 |
| | Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users | Q35966865 |
| | Antiretroviral therapy in prevention of HIV and TB: update on current research efforts | Q36493044 |
| | Contemporary costs of HIV healthcare in the HAART era | Q36550975 |
| | Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States | Q36875336 |
| | Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. | Q37175647 |
| | Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel | Q37234205 |
| | Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel | Q37773748 |
| | The impact of disease stage on direct medical costs of HIV management: a review of the international literature | Q37823559 |
| | Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. | Q41002448 |
| | Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel | Q41513115 |
| | Distribution of health care expenditures for HIV-infected patients | Q42699465 |
| | Determinants of the cost of health services used by veterans with HIV. | Q43428451 |
| | Decline in deaths from AIDS due to new antiretrovirals | Q44184848 |
| | Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. | Q44192276 |
| | Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries | Q46391119 |
| | Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy | Q46624490 |
| | Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel | Q50105738 |
| | Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. | Q50145200 |
| | Estimating log models: to transform or not to transform? | Q52058429 |
| | Bias and causal associations in observational research. | Q52936961 |
| | Effect of CD4+ cell count measurement variability on staging HIV-1 infection | Q67885079 |
| | Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel | Q74770726 |
| P433 | issue | 4 | |
| P921 | main subject | Canada | Q16 |
| | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 362-369 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Medical Care | Q15762119 |
| P1476 | title | Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011. | |
| P478 | volume | 52 | |